By a News Reporter-Staff News Editor at Clinical Trials Week -- BioClinica(®), Inc., the world's leading provider of medical imaging and cardiovascular safety services for the pharmaceutical, biotechnology, and medical device industries, announced that their neuroscience clinical trial experts will present recent clinical trial progress on the front against Alzheimer's Disease (AD) at this year's Alzheimer's Association International Conference (AAIC) in Copenhagen Denmark on July 12-17(th). BioClinica's deep neuroscience expertise will be showcased in a series of key presentations which include 6 scientific posters and an oral presentation, as well as an invitation to chair a session on neuroimaging (see also BioClinica, Inc.).
Several of BioClinica's neuroscience experts, including Joyce Suhy, PhD, Gregory Klein, PhD, and Chahin Pachai, PhD, will be on hand at the conference to discuss important scientific work related to brain imaging for advancing Alzheimer's disease (AD) clinical trials. "Advances in brain imaging including PET and functional MRI are proving instrumental for accurate patient selection and evaluation of new treatments in clinical trials for AD," said Joyce Suhy, VP of Neuroscience at BioClinica. "We are excited for the opportunity to partner with and support pharmaceutical companies and researchers who are developing next generation treatments for AD." Dr. Suhy will also chair a session focused on neuroimaging in clinical trials which will highlight recent advances in the area of molecular imaging that provide clinicians with sophisticated tools for monitoring AD. This session will include a presentation co-authored by BioClinica team members, on the subject of recent trial progress using amyloid PET screening for early stage AD patient recruitment.
BioClinica is the world's foremost medical imaging core lab for neuroscience clinical trials. The company's extensive resources include a dedicated team of neuroradiologists, image processing scientists and molecular and functional imaging experts making BioClinica the leading authority in clinical trial services for Alzheimer's clinical trials. "The team at BioClinica continues to be at the forefront in the use advanced imaging modalities in Alzheimer's clinical trials, as is demonstrated by a diverse and extensive set of presentations at this year's conference," stated Michael Weiner, MD, Scientific Advisor at BioClinica.
BioClinica has supported the clinical development of numerous clinical trials in AD and related dementias with a broad range of expertise in advanced imaging assessments including structural and functional MRI and molecular tracers. For a complete list of BioClinica attendees at AAIC or to schedule a meeting with one of BioClinica's neuroscience experts, please visit BioClinica's website at www.bioclinica.com or contact Joyce Suhy at email@example.com.
Keywords for this news article include: Dementia, Tauopathies, Neuroscience, Brain Diseases, BioClinica Inc., Alzheimer Disease, Neurodegenerative Diseases, Clinical Trials and Studies, Central Nervous System Diseases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC